No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. : The VYNE Therapeutics (VYNE.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $5.75.
HC Wainwright & Co. : The VYNE Therapeutics (VYNE.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $5.75.
Zhitong FinanceMay 6 22:50
Buy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical Data
TipRanksMay 6 22:15
VYNE Therapeutics Says US FDA Clears Its Investigational New Drug Application for Potential Autoimmune Treatment
VYNE Therapeutics (VYNE) said Monday the US Food and Drug Administration has cleared its Investigational New Drug Application for VYN202, its potential autoimmune disease treatment Vyne said it plans
MT NewswiresMay 6 20:51
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersMonogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. Allarity Therapeutics (NASDAQ:ALLR) s
BenzingaMay 6 20:06
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD
GlobeNewswireMay 6 20:00
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligoBRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc.
GlobeNewswireMay 1 20:00
No Data
No Data